EGFR and non-small cell lung carcinoma: Although further study is required to confirm the usefulness of vorinostat in combination with gefitinib in EGFR-mutant NSCLC, our study suggests the potential benefit of vorinostat for improving the efficacy of EGFR-TKIs in EGFR-mutant NSCLC.